RNS Number : 8965D
Proximagen Group PLC
23 May 2012
23 May 2012
Proximagen Group plc
Appointment of Nominated Adviser and Broker
London, UK, 23 May 2012 - Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on the treatment of disorders of the central nervous system and inflammatory diseases, announces the appointment of Cenkos Securities plc as its Nominated Adviser and Broker with immediate effect.
Proximagen Group plc Tel: +44 (0)20
Kenneth Mulvany, Chief Executive
James Hunter, Finance Director
Cenkos Securities plc (Nominated Tel: +44 (0)20
Adviser and Broker) 7397 8900
M:Communications (Media enquiries) Tel: +44 (0)20
Mary-Jane Elliott / Sarah email@example.com
Macleod / Hollie Vile
Proximagen Group plc (AIM:PRX) is a European biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and inflammation.
The Company is developing potential new best-in-class therapeutics in its core disease areas including epilepsy, Parkinson's disease, and Alzheimer's disease, as well as in other areas such as inflammation, oncology and neuropathic pain.
Proximagen has a number of existing partnerships with pharmaceutical companies including GlaxoSmithKline, Upsher-Smith and Lundbeck, and is developing a broad pipeline of drug candidate programmes, with four programmes in clinical development and more than ten earlier stage assets being progressed.
Proximagen's strategy is to advance its pipeline with its partners and to acquire innovative drug candidates that complement its pipeline, with the objective of scaling up its risk-mitigated operating model and generating sustainable profits.
For more information, please visit www.proximagen.com.
This information is provided by RNS
The company news service from the London Stock Exchange